NL00150005Y4 - Common Stock
PHARVARIS NV
NASDAQ:PHVS (3/27/2024, 8:00:01 PM)
23.5
-0.19 (-0.8%)
Pharvaris NV operates as a clinical-stage biopharmaceutical company. The company is headquartered in Leiden, Zuid-Holland and currently employs 65 full-time employees. The company went IPO on 2021-02-05. The activity of the Company focuses on producing oral bradykinin B2-receptor antagonists and is advancing new alternatives to injected therapies for all sub-types of hereditary angioedema (HAE).
PHARVARIS NV
J.H. Oortweg 21
Leiden ZUID-HOLLAND
CEO: Berndt Modig
Employees: 65
Website: https://pharvaris.com/
The company announced the initiation of RAPIDe-3, the Phase 3 clinical trial evaluating the efficacy and safety of deucrictibant immediate-release capsule...
ZUG, Switzerland, March 06, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor...
ZUG, Switzerland, March 05, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor...
Here you can normally see the latest stock twits on PHVS, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: